FDA Postpones Decision for Second Time On Lycopene and Cancer Health Claim Petition

The FDA has once again postponed its decision regarding pending health claim petitions due to lack of agency resources. Unfortunately, by delaying this process millions of people suffer by not learning the important health benefits of certain dietary supplements, such as Lycopene.

San Diego, CA (PRWEB) February 12, 2005 -- The FDA will not issue its decision on the pending American Longevity lycopene/cancer health claim petition until April 12, 2005. This is the second extension for this petition requested by the agency. The FDA was supposed to issue its decision on December 24, 2004 then extended its deadline until February 11, 2005. In recent months the agency has asked for extensions in its review of seven other pending qualified health claim petitions citing a lack of agency resources.

Obviously, we are disappointed that there has been another delay in getting this important health information out to the general public," states Steve Wallach of American Longevity. However, we look forward to getting approval on this lycopene/cancer health claim petition in April."

American Longevity has submitted several Health Claim Petitions to the FDA and is responsible for the recently authorized Health Claim Petition for Selenium and its relationship to Cancer Risk Reduction. American Longevity has helped to defend the Health Claim Petition process through the courts and has submitted many official comments to the FDA on behalf of the nutrition industry, all in an effort to help consumers have more access to truthful information in order to base a more informed decision regarding their own health and wellness.

American Longevity is a leading designer of Dietary Supplements and cutting edge personal care and wellness lifestyle products. The company was founded in April of 1997 in San Diego, California by Joel D. Wallach BS, DVM, ND, and Ma Lan MD, MS. American Longevity markets its products worldwide, through a network of independent distributors.

###